Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.

A Tale of Two Giants: Pfizer Inc. vs Axsome Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, the financial strategies of industry leaders like Pfizer Inc. and emerging players such as Axsome Therapeutics, Inc. offer intriguing insights. Over the past decade, Pfizer's Selling, General, and Administrative (SG&A) expenses have consistently hovered around $14 billion annually, reflecting its expansive global operations and robust market presence. In contrast, Axsome Therapeutics, a burgeoning biotech firm, has seen its SG&A costs skyrocket by over 23,000% from 2014 to 2023, highlighting its aggressive growth strategy and increasing market footprint.

This stark contrast underscores the differing scales and strategies of these companies. While Pfizer's steady expenses indicate a mature, stable operation, Axsome's rapid increase suggests a dynamic, growth-oriented approach. As the pharmaceutical industry continues to innovate, understanding these financial trends provides valuable context for investors and industry watchers alike.